Epidemiological and clinical profiles of cutaneous leishmaniasis cases in Amhara National Regional State, Northwest Ethiopia: a multicenter retrospective study
https://doi.org/10.4081/dr.2024.10089
Accepted: 31 August 2024
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Cutaneous leishmaniasis (CL) is caused by Leishmania parasites. Ethiopia is one of the top ten countries with high CL load. Amhara National Regional State (ANRS) is one of the CL hotspot areas in Ethiopia. This study determined the epidemiology and clinical profiles of CL in ANRS. This study was conducted from April to October 2023 in eight Leishmaniasis Treatment Centres (LTCs). A data review was done from patients presenting to these centres between June 2018 and July 2023. Chi-square test and logistic regression were performed using SPSS-23. A total of 1729 CL patients were recorded. The overall burden of CL per 10,000 outpatients was 900. Most of the patients (71.1%) presented with localised cutaneous leishmaniasis (LCL). The patients were from 112 districts. About 12% of the patients lived with the disease for over a year without treatment. Multiple-time comer patients accounted for 13.2% of the patients. Cutaneous leishmaniasis is still a major public health problem in ANRS. One-third of CL patients presented with the MCL clinical form. There was longer delay among CL patients for seeking diagnosis and treatment. Large scale community based study and traditional and modern treatment centers focused studies should be included to estimate the actual number of CL in the region. Follow-up and molecular studies are important to better understand the clinical features of the disease. Moreover, awareness of the community about the CL prevention and control help the patients to get early diagnosis and treatment.
Ruiz-Postigo JA, Grout L, Jain S. Global leishmaniasis surveillance, 2017–2018, and first report on 5 additional indicators Weekly epidemiological record 2020;25:165-280.
Singh OP, Sundar S. Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects. Front Immunol. 2014;5:296. DOI: https://doi.org/10.3389/fimmu.2014.00296
Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet. 2018;392:951-70. DOI: https://doi.org/10.1016/S0140-6736(18)31204-2
World Health Organization (WHO). Leishmaniasis, 2022.
den Boer M, Argaw D, Jannin J, et al. Leishmaniasis impact and treatment access. Clin Microbiol Infect. 2011;17:1471-7. DOI: https://doi.org/10.1111/j.1469-0691.2011.03635.x
Reithinger R, Dujardin JC, Louzir H, et al. Cutaneous leishmaniasis. Lancet Infect Dis. 2007;7:581-96. DOI: https://doi.org/10.1016/S1473-3099(07)70209-8
Neitzke-Abreu HC, Venazzi MS, de Lima Scodro RB, et al. Cutaneous leishmaniasis with atypical clinical manifestations: Case report. IDCases. 2014;1:60-2. DOI: https://doi.org/10.1016/j.idcr.2014.07.003
Libardo J. Gómez RvW, Lena van Selm, Alberto Rivera, et al. Stigma, participation restriction and mental distress in patients affected by leprosy, cutaneous leishmaniasis and Chagas disease: a pilot study in two co-endemic regions of eastern Colombia. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2019:1-7.
Bennis I, Thys S, Filali H, et al. Psychosocial impact of scars due to cutaneous leishmaniasis on high school students in Errachidia province, Morocco. Infect Dis Poverty. 2017;6:46. DOI: https://doi.org/10.1186/s40249-017-0267-5
Mengistu G, Laskay T, Gemetchu T, et al. Cutaneous leishmaniasis in south-western Ethiopia: Ocholo revisited. Trans R Soc Trop Med Hyg. 1992;86:149-53. DOI: https://doi.org/10.1016/0035-9203(92)90546-O
Yizengaw E, Nibret E, Yismaw G, et al. Cutaneous leishmaniasis in a newly established treatment centre in the Lay Gayint district, Northwest Ethiopia. Skin health and Disease. 2023:1-8. DOI: https://doi.org/10.1002/ski2.229
Shita EY, Nibret E, Munshea A, et al. Burden and risk factors of cutaneous leishmaniasis in Ethiopia: a systematic review and meta-analysis. Int J Dermatol. 2022;61:1336-45. DOI: https://doi.org/10.1111/ijd.16265
Alvar J, Canavate C, Gutierrez-Solar B, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev. 1997;10:298-319. DOI: https://doi.org/10.1128/CMR.10.2.298
Alvar J, Velez ID, Bern C, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7:e35671. DOI: https://doi.org/10.1371/journal.pone.0035671
Guideline for Diagnosis, Treatment and Prevention of Leishmaniasis in Ethiopia 2013.
Gashaw G. Yizengaw E, Sebsibe B, et al. Clinical Manifestations of Cutaneous Leishmaniasis (CL): Does Elevated Blood Sugar Level have Implications for Clinical Management of CL? Ethiopian Journal of Health Development. 2023;37.
Eshetu B, Mamo H. Cutaneous leishmaniasis in north-central Ethiopia: trend, clinical forms, geographic distribution, and determinants. Trop Med Health. 2020;48:39. DOI: https://doi.org/10.1186/s41182-020-00231-w
van Henten S, Bialfew F, Hassen S, et al.Treatment of cutaneous leishmaniasis with sodium stibogluconate and allopurinol in a routine setting in Ethiopia: Clinical and Patient-Reported Outcomes and Operational Challenges. Trop Med Infect Dis. 2023;8. DOI: https://doi.org/10.1101/2023.07.05.23292210
Neway B.Y.S, Mebrat B, Ayalew G. Prevalence of cutaneous leishmaniasis in alert center, retrospective analysis, Addis Ababa. Journal of Health Systems and Policies. 2021;3:110-21. DOI: https://doi.org/10.52675/jhesp.949565
van Henten S, Adriaensen W, Fikre H, et al. Cutaneous Leishmaniasis Due to Leishmania aethiopica. EClinicalMedicine. 2018;6:69-81. DOI: https://doi.org/10.1016/j.eclinm.2018.12.009
Fikre H, Mohammed R, Atinafu S, et al. Clinical features and treatment response of cutaneous leishmaniasis in North-West Ethiopia. Trop Med Int Health. 2017;22:1293-301. DOI: https://doi.org/10.1111/tmi.12928
Yohannes M, Abebe Z, Boelee E. Prevalence and environmental determinants of cutaneous leishmaniasis in rural communities in Tigray, northern Ethiopia. PLoS Negl Trop Dis. 2019;13:e0007722. DOI: https://doi.org/10.1371/journal.pntd.0007722
Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from infancy to old age. Proc Biol Sci. 2015;282:20143085. DOI: https://doi.org/10.1098/rspb.2014.3085
Davies CR, Gavgani ASM. Age, acquired immunity and the risk of visceral leishmaniasis: a prospective study in Iran. Parasitology. 1999;119:247-57. DOI: https://doi.org/10.1017/S0031182099004680
Okwor I, Mou Z, Liu D, et al. Protective immunity and vaccination against cutaneous leishmaniasis. Front Immunol. 2012;3:128. DOI: https://doi.org/10.3389/fimmu.2012.00128
Seife AKBT, Zewdu TF, Ayal A, et al. Treatment Patterns and Effectivness of Anti-Leishmaniasis Agents for Patients with Cutaneous Leishmaniasis at Boru Meda Hospital, South Wollo, North East Ethiopia, 2017/18. Journal of Clinical & Experimental Dermatology Research. 2018;9. DOI: https://doi.org/10.4172/2155-9554.1000450
Negera E, Gadisa E, Yamuah L, et al. Outbreak of cutaneous leishmaniasis in Silti woreda, Ethiopia: risk factor assessment and causative agent identification. Trans R Soc Trop Med Hyg. 2008;102:883-90. DOI: https://doi.org/10.1016/j.trstmh.2008.03.021
Tilahun WAT, Mulatu G. Magnitude and associated factors of cutaneous leishmaniasis; in Mekelle city, Ayder referral hospital, Tigray, Northern Ethiopia, 2014 Clinical Medicine Research. 2014;3:. DOI: https://doi.org/10.11648/j.cmr.20140306.16
Bisetegn H, Zeleke AJ, Gadisa E, et al. Clinical, parasitological and molecular profiles of Cutaneous Leishmaniasis and its associated factors among clinically suspected patients attending Borumeda Hospital, North-East Ethiopia. PLoS Negl Trop Dis. 2020;14:e0008507. DOI: https://doi.org/10.1371/journal.pntd.0008507
van Henten S, Tesfaye AB, Abdela SG, et al. Miltefosine for the treatment of cutaneous leishmaniasis-A pilot study from Ethiopia. PLoS Negl Trop Dis. 2021;15:e0009460. DOI: https://doi.org/10.1371/journal.pntd.0009460
Cantanhede LM, da Silva Junior CF, Ito MM, et al. Further Evidence of an Association between the Presence of Leishmania RNA Virus 1 and the Mucosal Manifestations in Tegumentary Leishmaniasis Patients. PLoS Negl Trop Dis. 2015;9:e0004079. DOI: https://doi.org/10.1371/journal.pntd.0004079
Aberra L, Abera A, Belay T, et al. Evaluation of microcapillary culture method for the isolation of Leishmania aethiopica parasites from patients with cutaneous lesions in Ethiopia. Diagn Progn Res. 2019;3:4. DOI: https://doi.org/10.1186/s41512-019-0051-z
A Lemma WAF, T Gemetchu, P M Preston, et al. A Studies on leishmaniasis in Ethiopia. I. Preliminary investigations into the epidemiology of cutaneous leishmaniasis in the highlands. Ann Trop Med Parasitol. 1969;63:455-72. DOI: https://doi.org/10.1080/00034983.1969.11686649
Padovese V, Terranova M, Toma L, et al. Cutaneous and mucocutaneous leishmaniasis in Tigray, northern Ethiopia: clinical aspects and therapeutic concerns. Trans R Soc Trop Med Hyg. 2009;103:707-11. DOI: https://doi.org/10.1016/j.trstmh.2009.02.023
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
